Johns Hopkins Medicine awarded NIH grant to explore the impacts of psilocybin on tobacco addiction

Johns Hopkins Medicine was awarded a grant from the National Institutes of Health (NIH) to explore the potential impacts of psilocybin on tobacco addiction. This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic psychedelic, consistent with a recent study published online that searched NIH funding and found zero grants were awarded between 2006 and 2020. Johns Hopkins Medicine will lead the multisite, three-year study in collaboration with University of Alabama at Birmingham and New York University.

The study will be conducted simultaneously at the three institutions to diversify the pool of participants and increase confidence that results apply to a wide range of people who smoke. The grant, totaling nearly $4 million, is funded by NIH's National Institute on Drug Abuse.

The historical importance of this grant is monumental. We knew it was only a matter of time before the NIH would fund this work because the data are so compelling, and because this work has demonstrated to be safe. Psilocybin does have very real risks, but these risks are squarely mitigated in controlled settings through screening, preparation, monitoring and follow-up care."

Matthew Johnson, Ph.D., Principal Investigator, Susan Hill Ward Professor in Psychedelics and Consciousness, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine

Over the last 20 years, there has been a growing renaissance of research with classic psychedelics, which are the pharmacological class of compounds that includes psilocybin and LSD. These studies have been largely funded by philanthropy, resulting in impressive clinical findings for cancer-related existential distress, major depressive disorder and substance use disorders.

Johnson initiated this line of research testing psilocybin for tobacco smoking cessation 13 years ago. A pilot study published in 2014 showed very high abstinence rates, much larger than those seen with traditional smoking cessation medications and therapies.

The current double-blind randomized trial involves psilocybin sessions as well as cognitive behavioral therapy — a type of talk therapy (psychotherapy) focused on pinpointing negative patterns of thought that can lead to behavioral and mental health problems. The researchers suggest psilocybin might help break the addictive pattern of thoughts and behaviors that has become ingrained after years of smoking, thus helping people to quit the habit.

Psilocybin, a compound found in so-called magic mushrooms, produces visual and auditory illusions and profound changes in consciousness. Combined with preparation and structured support, psilocybin has shown promise for treating a range of addictions and mental health disorders.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests